Outcome Evaluation in Pre-Trastuzumab Era between Different Breast Cancer Phenotypes: A Population-Based Study on Italian Women

Menard S. , Fortis S. , Castiglioni F. , Agresti R. , Balsari A. : HER2 as a prognostic factor in breast cancer. Oncology, 61 Suppl 2: 67–72, 2001.

Wang S.C. , Hung M.C. : HER2 overexpression and cancer targeting. Semin Oncol, 28 (5 Suppl 16): 115–124, 2001.

Huang E. , Cheng S.H. , Dressman H. , Pittman J. , Tsou M.H. , Horng C.F. , Bild A. , Iversen E.S. , Liao M. , Chen C.M. , West M. , Nevins J.R. , Huang A. : Gene expression predictors of breast cancer outcomes. Lancet, 361(9369): 1590–1596, 2003.

Sorlie T. , Perou C.M. , Tibshirani R. , Aas T. , Geisler S. , Johnsen H. , Hastie T. , Eisen M.B. , van de Rijn M. , Jeffrey SS , Thorsen T. , Quist H. , Matese J.C. , Brown P.O. , Botstein D. , Eystein Lonning P. , Borresen-Dale A.L. : Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A, 98: 10869–10874, 2001.

Sotiriou C. , Neo S.Y. , McShane L.M. , Korn E.L. , Long P.M. , Jazaeri A. , Martiat P. , Fox S.B. , Harris A.L. , Liu E.T. : Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A, 100: 10393–10398, 2003.

Perou C.M. , Sorlie T. , Eisen M.B. , van de Rijn M. , Jeffrey S.S. , Rees C.A. , Pollack J.R. , Ross D.T. , Johnsen H. , Akslen L.A. , Fluge O. , Pergamenschikov A. , Williams C. , Zhu S.X. , Lonning P.E. , Borresen-Dale A.L. , Brown P.O. , Botstein D. : Molecular portraits of human breast tumours. Nature, 406: 747–752, 2000.

Sotiriou C. , Powles T.J. , Dowsett M. , Jazaeri A.A. , Feldman A.L. , Assersohn L. , Gadisetti C. , Libutti S.K. , Liu E.T. : Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res, 4: R3, 2002.

van't Veer L.J. , Dai H. , van de Vijver M.J. , He Y.D. , Hart A.A. , Mao M. , Peterse H.L. , van der Kooy K. , Marton M.J. , Witteveen A.T. , Schreiber G.J. , Kerkhoven R.M. , Roberts C. , Linsley P.S. , Bernards R. , Friend S.H. : Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415: 530–536, 2002.

van de Vijver M.J. , He Y.D. , van't Veer L.J. , Dai H. , Hart A.A. , Voskuil D.W. , Schreiber G.J. , Peterse J.L. , Roberts C. , Marton MJ , Parrish M. , Atsma D. , Witteveen A. , Glas A. , Delahaye L. , van der Velde T. , Bartelink H. , Rodenhuis S. , Rutgers E.T. , Friend S.H. , Bernards R. : A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med, 347: 1999–2009, 2002.

Sorlie T. , Tibshirani R. , Parker J. , Hastie T. , Marron J.S. , Nobel A. , Deng S. , Johnsen H. , Pesich R. , Geisler S. , Demeter J. , Perou C.M. , Lonning P.E. , Brown P.O. , Borresen-Dale A.L. , Botstein D. : Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A, 100: 8418–8423, 2003.

Cheang M.C.U. , Chia S.K. , Voduc D. , Gao D. , Leung S. , Snider J. , Watson M. , Davies S. , Bernard P.S. , Parker J.S. , Perou C.M. , Ellis M.J. , Nielsen T.O. : Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst, 101: 736–750, 2009.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ and Panel members: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol, 22: 1736–1747, 2011.

Foulkes W.D. , Stefansson I.M. , Chappuis P.O. , Begin L.R. , Goffin J.R. , Wong N. , Trudel M. , Akslen L.A. : Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst, 95: 1482–1485, 2003.

Modi S. , DiGiovanna M.P. , Lu Z. , Moskowitz C. , Panageas K.S. , Van Poznak C. , Hudis C.A. , Norton L. , Tan L. , Stern D.F. , Carter D. , Seidman A.D. : Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancer. Cancer Invest, 23: 483–487, 2005.

Dhesy-Thind B. , Pritchard K.I. , Messersmith H. , O'Malley F. , Elavathil L. , Trudeau M. : HER2/neu in systemic therapy for women with breast cancer: a systematic review. Breast Cancer Res Treat, 109: 209–229, 2008.

Gennari A. , Sormani M.P. , Pronzato P. , Puntoni M. , Colozza M. , Pfeffer U. , Bruzzi P. : HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst, 100: 14–20, 2008.

Park S. , Koo J.S. , Kim M.S. , Park H.S. , Lee J.S. , Lee J.S. , Kim S.I. , Park B.W. : Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry. Breast, 21: 50–57, 2012.

Voduc K.D. , Cheang M.C. , Tyldesley S. , Gelmon K. , Nielsen T.O. , Kennecke H. : Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol, 28: 1684–1691, 2010.

Dawood S. , Hu R. , Homes M.D. , Collins L.C. , Schnitt S.J. , Connolly J. , Colditz G.A. , Tamimi R.M. : Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study. Breast Cancer Res Treat, 126: 185–192, 2011.

Fritz A. : International classification of diseases for oncology (ICD-O). Geneva: World Health Organization; 2000.

Kaplan H.G. , Malmgren J.A. : Impact of triple negative phenotype on breast cancer prognosis. Breast J, 14: 456–463, 2008.

Shoenfeld D. : Partial residuals for the proportional hazard regression model. Biometrika, 69: 239, 1982.

Van Houwelingen J.C. , le Cessie S. : Predictive value of statistical models. Stat Med 9: 1303–1325, 1990.

Dent R. , Trudeau M. , Pritchard K.I. , Hanna W.M. , Kahn H.K. , Sawka C.A. , Lickley L.A. , Rawlinson E. , Sun P. , Narod S.A. : Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res, 13: 4429–4434, 2007.

Jatoi I. , Anderson W.F. , Jeong J.H. , Redmond C.K. : Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol. 29: 2301–2304, 2011.

Kaplan H.G. , Malmgren J.A. : Disease-specific survival in patient-detected breast cancer. Clin Breast Cancer, 7: 133–140, 2006.

Romond E.H. , Perez E.A. , Bryant J. , Suman V.J. , Geyer C.E. Jr. , Davidson N.E. , Tan-Chiu E. , Martino S. , Paik S. , Kaufman P.A. , Swain S.M. , Pisansky T.M. , Fehrenbacher L. , Kutteh L.A. , Vogel V.G. , Visscher D.W. , Yothers G. , Jenkins R.B. , Brown A.M. , Dakhil S.R. , Mamounas E.P. , Lingle W.L. , Klein P.M. , Ingle J.N. , Wolmark N. : Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353: 1673–1684, 2005.

Piccart-Gebhart M.J. , Procter M. , Leyland-Jones B. , Goldhirsch A. , Untch M. , Smith I. , Gianni L. , Baselga J. , Bell R. , Jackisch C. , Cameron D. , Dowsett M. , Barrios C.H. , Steger G. , Huang C.S. , Andersson M. , Inbar M. , Lichinitser M. , Lang I. , Nitz U. , Iwata H. , Thomssen C. , Lohrisch C. , Suter T.M. , Ruschoff J. , Suto T. , Greatorex V. , Ward C. , Straehle C. , McFadden E. , Dolci M.S. , Gelber R.D. : Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353: 1659–1672, 2005.

Gonzalez-Angulo A.M. , Litton J.K. , Broglio K.R. , Meric-Bernstam F. , Rakkhit R. , Cardoso F. , Peintinger F. , Hanrahan E.O. , Sahin A. , Guray M. , Larsimont D. , Feoli F. , Stranzl H. , Buchholz T.A. , Valero V. , Theriault R. , Piccart-Gebhart M. , Ravdin P.M. , Berry D.A. , Hortobagyi G.N. : High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol, 27: 5700–5706, 2009.

Menard S. , Casalini P. , Campiglio M. , Pupa S. , Agresti R. , Tagliabue E. : HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol, 12: S15–19, 2001.

Kavanagh D.O. , Chambers G. , O'Grady L. , Barry K.M. , Waldron R.P. , Bennani F. , Eustace P.W. , Tobbia I. : Is overexpression of HER-2 a predictor of prognosis in colorectal cancer? BMC Cancer, 9: 1, 2009.